Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease

Kwee Yong, MD PhD, Samantha Hinsley, MSc, BSc, Ruth M De Tute, BSc,MSc, Debbie Sherratt, Sarah R Brown, PhD MSc, BSc, Louise Flanagan, PhD, Catherine Williams, Jamie Cavenagh, MD PhD, Martin Kaiser, MD, Neil K Rabin, MD, Karthik Ramasamy, MD PhD, Mamta Garg, Holger W. Auner, MD PhD, Gareth Morgan, MD, Faith E. Davies, MD, Roger G. Owen

Blood (2018) 132 (Supplement 1): 802.

https://doi.org/10.1182/blood-2018-99-116426

Published: 2018

Journal Articles

Real World Analysis of the Incidence and Impact of Hypertension and Cardiac Toxicity Associated with Carfilzomib for Patients with Multiple Myeloma

Selina J Chavda, MBBS, BSc, MRCP, Rachael Pocock, MBBS, BSc, MRCP, Simon Cheesman, BPharm, Emma Dowling, Puneet Verma, MRPharmS, Malcolm Walker, MBBS, MBChB, MD FRCP, Charalampia Kyriakou, MD PhD, Ashutosh D. Wechalekar, Neil K Rabin, MD, Kwee Yong, MD PhD, Rakesh Popat, MBBS, BSc, MRCP, FRCPath, PhD

Blood (2018) 132 (Supplement 1): 3255.

https://doi.org/10.1182/blood-2018-99-113832

Published: 2018

Journal Articles

Encouraging Outcomes for Patients with Multiple Myeloma Treated in Early Phase Clinical Trials: A Single Centre and Meta-Analysis

Anna Cowley, MBBS, BSc, MRCP, FRCPath, Jenny O'Nions, MBBChir, PhD MRCP, FRCPath, Hakim-Moulay Dehbi, PhD, Dima El-Sharkawi, MBBS BSc FRCPath MD, William Townsend, MD FRCPath, Kwee Yong, MD PhD, Rakesh Popat, MBBS, BSc, MRCP, FRCPath, PhD

Blood (2018) 132 (Supplement 1): 5663.

https://doi.org/10.1182/blood-2018-99-118706

Published: 2018

Journal Articles

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

Kwee Yong, MD PhD, Samantha Hinsley, MSc, BSc, Debbie Sherratt, Jessica Kendall, BSc, MSc, Sarah R Brown, PhD MSc, BSc, Louise Flanagan, PhD, Catherine Williams, Jamie Cavenagh, MD PhD, Martin Kaiser, MD, Neil K Rabin, MD, Karthik Ramasamy, MD PhD, Mamta Garg, Holger W. Auner, MD PhD, Stephen F. Hawkins, MBChB, MRCP, Ceri Bygrave, MD FRCPath, MPhil, Ruth M De Tute, BSc,MSc, Gareth Morgan, MD, Faith E. Davies, MD, Roger G. Owen

Blood (2018) 132 (Supplement 1): 306.

https://doi.org/10.1182/blood-2018-99-116624

Published: 2018

Journal Articles

Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018

Karthik Ramasamy, MD PhD, Spyros Kolovos, PhD, Guido Nador, MD, Rosemarie Finley, Matthew Streetly, MD, Bhuvan Kishore, Neil K Rabin, MD, Andrew D Chantry, PhD MD, Kwee Yong, MD PhD, John Ashcroft, Stella Bowcock, MD BA, FRCP, FRCPath, MA, Mark T Drayson, Daniel Prieto-Alhambra, PhD MD, Cyrus Cooper, OBE, DL, FMedSci, Muhammad Kassim Javaid, MD PhD, Rafael Pinedo-Villanueva, PhD

Blood (2018) 132 (Supplement 1): 4743.

https://doi.org/10.1182/blood-2018-99-114736

Published: 2018

Journal Articles

Factors Influencing Short Term In Vivo Biodistribution of Human Bone Marrow Derived Mesenchymal Stem Cells (hMSCs) in a Xenogeneic Animal Model.

Charalampia Kyriakou, MD, Neil Rabin, MD, Amit Nathwani, MD,PhD, Arnold Pizzey, David C. Linch, MD,PhD, Kwee Yong, MD,PhD

Blood (2006) 108 (11): 3182.

https://doi.org/10.1182/blood.V108.11.3182.3182

Published: 2006

Journal Articles

Role of Allogeneic Stem Cell Transplantation in Lymphoplasmacytic Lymphoma. Analysis of 61 Cases from the European Bone Marrow Registry (EBMT).

Charalampia A. Kyriakou, MD, Anthony H. Goldstone, MD, Anna Sureda, MD, Kwee Yong, MD, PhD, Goli Taghipour, Carmen Ruiz de Elvira, David C. Linch, MD, PhD, Stephen Mackinnon, MD, Norbert Schmitz, MD, PhD

Blood (2004) 104 (11): 3326.

https://doi.org/10.1182/blood.V104.11.3326.3326

Published: 2004

NARROW

Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease

Real World Analysis of the Incidence and Impact of Hypertension and Cardiac Toxicity Associated with Carfilzomib for Patients with Multiple Myeloma

Encouraging Outcomes for Patients with Multiple Myeloma Treated in Early Phase Clinical Trials: A Single Centre and Meta-Analysis

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018

Factors Influencing Short Term In Vivo Biodistribution of Human Bone Marrow Derived Mesenchymal Stem Cells (hMSCs) in a Xenogeneic Animal Model.

Role of Allogeneic Stem Cell Transplantation in Lymphoplasmacytic Lymphoma. Analysis of 61 Cases from the European Bone Marrow Registry (EBMT).

Email alerts

ASH Publications

American Society of Hematology

Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease

Real World Analysis of the Incidence and Impact of Hypertension and Cardiac Toxicity Associated with Carfilzomib for Patients with Multiple Myeloma

Encouraging Outcomes for Patients with Multiple Myeloma Treated in Early Phase Clinical Trials: A Single Centre and Meta-Analysis

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018

Factors Influencing Short Term In Vivo Biodistribution of Human Bone Marrow Derived Mesenchymal Stem Cells (hMSCs) in a Xenogeneic Animal Model.

Role of Allogeneic Stem Cell Transplantation in Lymphoplasmacytic Lymphoma. Analysis of 61 Cases from the European Bone Marrow Registry (EBMT).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only